Active Volume Stock: Biocept, Inc. (NASDAQ:BIOC)

19

Biocept, Inc. (NASDAQ:BIOC) currently has a “Hold” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

Biocept, Inc. (NASDAQ:BIOC) lost -33.04 Percent and closed its previous trading session at $0.77. The stock traded with the average Volume of 497.37 Million at the end of last session.

Biocept, Inc. (NASDAQ:BIOC) has the Market Capitalization of 24.06 Million. The Stock has its 52-week High of $3.390 and 52-Week Low of $0.600 and it touched its 52-week high on 01/11/17 and 52-Week Low on 11/15/17.

The company reported its last earnings Actual EPS of $0.07/share. While, the analyst predicted that the company could provide an EPS of $0.09/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.02/share which shows an Earnings Surprise of -22.2 Percent.

Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Biocept, Inc. (NASDAQ:BIOC) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 4.9% where SMA50 and SMA200 are -19.72% and -46.08% respectively.

The company shows its Return on Assets (ROA) value of -165.3%. The Return on Equity (ROE) value stands at -518.1%.

Biocept, Inc. (NASDAQ:BIOC) currently has a Weekly Volatility of 23.45% percent while its Monthly Volatility is at 13.88% percent. While talking about Performance of the Stock, Biocept, Inc. currently has a Weekly performance of 3.36%, monthly performance percentage is -12.44 percent, Quarterly performance is -41.67 percent, 6 months performance shows a percent value of -45% and Yearly Performance is -10.57 percent.

Company Profile:

Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California.

 

SHARE